PBPK Modelling of PROTACs: Learnings from ARV-110 as a Case Example.
Saved in:
| Title: | PBPK Modelling of PROTACs: Learnings from ARV-110 as a Case Example. |
|---|---|
| Authors: | Salem F; DMPK Modelling, DMPK, GSK, Stevenage, UK., Tabatabaeian Nimavardi A; Certara UK Limited, Simcyp Division, 1 Concourse Way, Level 2 Acero, Sheffield, UK., Srivastava A; Oncology DMPK, Oncology R&D, AstraZeneca, Cambridge, CB2 0AA, UK., Krollik K; Global Drug Product Development, the healthcare business of Merck KGaA, Darmstadt, Germany., Reichel A; Preclinical Modeling & Simulation, Pharma R&D, Bayer AG, Berlin, Germany., Cebrian D; Integrated Drug Discovery, Selvita SA, Podole 79, 30-394, Kraków, Poland., Taskar KS; DMPK Modelling, DMPK, GSK, Stevenage, UK., Yates JWT; DMPK Modelling, DMPK, GSK, Stevenage, UK., Rynn C; Translational PKPD and Clinical Pharmacology, Roche Products Ltd, Hexagon Place, 6 Falcon Way, Welwyn Garden City, UK., Duevel HM; NCE DMPK, the healthcare business of Merck KGaA, Darmstadt, Germany. heide.duevel@merckgroup.com. |
| Source: | The AAPS journal [AAPS J] 2026 Mar 27; Vol. 28 (3). Date of Electronic Publication: 2026 Mar 27. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association of Pharmaceutical Scientists Country of Publication: United States NLM ID: 101223209 Publication Model: Electronic Cited Medium: Internet ISSN: 1550-7416 (Electronic) Linking ISSN: 15507416 NLM ISO Abbreviation: AAPS J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
